BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer.

Elshazly, Ahmed M; Sinanian, Melanie M; Neely, Victoria; Chakraborty, Eesha; Alshehri, Muruj A; McGrath, Michael K; Harada, Hisashi; Schoenlein, Patricia V; Gewirtz, David A

Elshazly, Ahmed M; Sinanian, Melanie M; Neely, Victoria; Chakraborty, Eesha; Alshehri, Muruj A; McGrath, Michael K; Harada, Hisashi; Schoenlein, Patricia V; Gewirtz, David A.

Afiliação

Elshazly AM; Departments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Sinanian MM; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Neely V; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
Chakraborty E; Departments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Alshehri MA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
McGrath MK; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Harada H; Philips Institute for Oral Health Research, School of Dentistry, Virginia Commonwealth University, Richmond, VA 23298, USA.
Schoenlein PV; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Gewirtz DA; C. Kenneth and Dianne Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA 23298, USA.

Cancers (Basel) ; 15(16)2023 Aug 11.

Article em En | MEDLINE | ID: mdl-37627092

Palavras-chave

ABBV-744; ARV-825; BRD4; c-Myc; p53; senescence

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google